SEC Comment Letter 0000000000-23-009892 to Q BioMed Inc. (QBIO) (CIK 0001596062)
Q BioMed Inc. (QBIO) (CIK 0001596062)
Date: Sept. 7, 2023 · CIK: 0001596062 · Accession: 0000000000-23-009892
AI Filing Summary & Sentiment
File numbers found in text: 000-55535
Letter
United States securities and exchange commission logo September 7, 2023 Denis Corin President, Chief Executive Officer and Director Q BioMed Inc. c/o Ortoli Rosenstadt LLP 366 Madison Avenue , 3rd Floor New York , NY 10017 Re:Q BioMed Inc. Form 10-K for the Fiscal Year Ended November 30, 2022 Filed May 26, 2023 File No. 000-55535 Dear Denis Corin: We issued comments on the above captioned filing on July 3, 2023. On August 10, 2023, we issued a follow-up letter informing you that those comments remained outstanding and unresolved, and absent a substantive response, we would act consistent with our obligations under the federal securities laws. As you have not provided a substantive response, we are terminating our review and will take further steps as we deem appropriate. These steps include releasing publicly, through the agency's EDGAR system, all correspondence, including this letter, relating to the review of your filing, consistent with the staff s decision to publicly release comment and response letters relating to disclosure filings it has reviewed. Please contact Angela Connell at (202) 551-3426 or Suzanne Hayes at (202) 551- 3675 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
September 7, 2023
Denis Corin
President, Chief Executive Officer and Director
Q BioMed Inc.
c/o Ortoli Rosenstadt LLP
366 Madison Avenue , 3rd Floor
New York , NY 10017
Re:Q BioMed Inc.
Form 10-K for the Fiscal Year Ended November 30, 2022
Filed May 26, 2023
File No. 000-55535
Dear Denis Corin:
We issued comments on the above captioned filing on July 3, 2023. On August 10, 2023,
we issued a follow-up letter informing you that those comments remained outstanding and
unresolved, and absent a substantive response, we would act consistent with our obligations
under the federal securities laws.
As you have not provided a substantive response, we are terminating our review and will
take further steps as we deem appropriate. These steps include releasing publicly, through the
agency's EDGAR system, all correspondence, including this letter, relating to the review of your
filing, consistent with the staff s decision to publicly release comment and response letters
relating to disclosure filings it has reviewed.
Please contact Angela Connell at (202) 551-3426 or Suzanne Hayes at (202) 551-
3675 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences